{"id":"W4249384979","doi":"10.1200/jco.2019.37.15_suppl.7532","title":"Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; ABVD; Brentuximab vedotin; Population; Dacarbazine; Internal medicine; Nuclear medicine; Oncology; Chemotherapy; Lymphoma; Hodgkin lymphoma; Vincristine; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01246702,0.0004834049,0.001584405,0.0006327818,0.0002761961,0.001436113,0.0009992579,0.0009030444,0.0009290923],"category_scores_gemma":[0.003800148,0.0003053061,0.001380444,0.001134157,0.0003082023,0.001068596,0.0005245336,0.001686587,0.000233342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001345987,"about_ca_system_score_gemma":0.001478706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002240981,"about_ca_topic_score_gemma":0.005789297,"domain_scores_codex":[0.9978916,0.001123114,0.0002316278,0.0001370062,0.0004407016,0.0001759416],"domain_scores_gemma":[0.9957432,0.001380639,0.001246509,0.0003283714,0.0005755512,0.0007257229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1211178,0.003943197,0.1041846,0.00367858,0.005753598,0.0004451591,0.000470171,0.002245083,0.01259293,0.0005991376,0.02130194,0.7236678],"study_design_scores_gemma":[0.1001642,0.1098801,0.5854092,0.002012376,0.01406009,0.00249861,0.0003805268,0.002590718,0.006348668,0.0009241852,0.1755873,0.0001439529],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8104608,0.1618268,0.00192021,0.005848797,0.001022424,0.002043641,0.008135032,0.0001735582,0.008568613],"genre_scores_gemma":[0.9111263,0.05393369,0.004301836,0.009732874,0.001031847,0.001865259,0.01508459,0.00009203904,0.002831588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01246702,"threshold_uncertainty_score":0.06593275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06538313009105307,"score_gpt":0.4175630762427917,"score_spread":0.3521799461517386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}